Eledon Pharmaceuticals Net Worth
Eledon Pharmaceuticals Net Worth Breakdown | ELDN |
Eledon Pharmaceuticals Net Worth Analysis
Eledon Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Eledon Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Eledon Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Eledon Pharmaceuticals' net worth analysis. One common approach is to calculate Eledon Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Eledon Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Eledon Pharmaceuticals' net worth. This approach calculates the present value of Eledon Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Eledon Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Eledon Pharmaceuticals' net worth. This involves comparing Eledon Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Eledon Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Eledon Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Eledon Pharmaceuticals' net worth research are outlined below:
| Eledon Pharmaceuticals generated a negative expected return over the last 90 days | |
| Eledon Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (36.18 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eledon Pharmaceuticals currently holds about 70.46 M in cash with (47.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.12, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 68.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Robinson James A. Jr. of 30870 shares of Eledon Pharmaceuticals at 4.04 subject to Rule 16b-3 |
Eledon Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Eledon Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eledon Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Eledon Pharmaceuticals Target Price Consensus
Eledon target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Eledon Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Strong Buy |
Most Eledon analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Eledon stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Eledon Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationEledon Pharmaceuticals Target Price Projection
Eledon Pharmaceuticals' current and average target prices are 3.51 and 12.50, respectively. The current price of Eledon Pharmaceuticals is the price at which Eledon Pharmaceuticals is currently trading. On the other hand, Eledon Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Eledon Pharmaceuticals Market Quote on 23rd of March 2025
Target Price
Analyst Consensus On Eledon Pharmaceuticals Target Price
Know Eledon Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eledon Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eledon Pharmaceuticals backward and forwards among themselves. Eledon Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Eledon Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Awm Investment Company Inc | 2024-12-31 | 1.1 M | Point72 Asset Management, L.p. | 2024-12-31 | 1.1 M | Alyeska Investment Group, L.p. | 2024-12-31 | 933.5 K | Sanofi | 2024-12-31 | 815 K | Zimmer Partners Lp | 2024-12-31 | 750 K | Geode Capital Management, Llc | 2024-12-31 | 663.1 K | Blackrock Inc | 2024-12-31 | 617.6 K | Boothbay Fund Management, Llc | 2024-12-31 | 341.9 K | Velan Capital Investment Management Lp | 2024-12-31 | 324 K | Bvf Inc | 2024-12-31 | 6.3 M | Ra Capital Management, Llc | 2024-12-31 | 3.6 M |
Follow Eledon Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 209.68 M.Market Cap |
|
Project Eledon Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.45) | (0.48) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.30) | (0.31) |
When accessing Eledon Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Eledon Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Eledon Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Eledon Pharmaceuticals' management efficiency
Eledon Pharmaceuticals has return on total asset (ROA) of (0.3336) % which means that it has lost $0.3336 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2589) %, meaning that it created substantial loss on money invested by shareholders. Eledon Pharmaceuticals' management efficiency ratios could be used to measure how well Eledon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of March 2025, Return On Tangible Assets is likely to drop to -0.21. In addition to that, Return On Capital Employed is likely to drop to -0.48. At this time, Eledon Pharmaceuticals' Non Currrent Assets Other are very stable compared to the past year. As of the 23rd of March 2025, Total Current Assets is likely to grow to about 150.9 M, while Total Assets are likely to drop about 89.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.43 | 2.31 | |
| Tangible Book Value Per Share | 2.43 | 2.31 | |
| Enterprise Value Over EBITDA | 0.24 | 0.25 | |
| Price Book Value Ratio | 1.69 | 1.61 | |
| Enterprise Value Multiple | 0.24 | 0.25 | |
| Price Fair Value | 1.69 | 1.61 | |
| Enterprise Value | 207.5 M | 217.8 M |
Management at Eledon Pharmaceuticals focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eledon Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eledon Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eledon Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eledon Pharmaceuticals Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 13th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Eledon Pharmaceuticals Earnings per Share Projection vs Actual
Eledon Pharmaceuticals Corporate Management
| Marina Escudero | VP Operations | Profile | |
| Gregory Flesher | Consultant | Profile | |
| Bryan JD | Corporate Counsel | Profile | |
| John Herberger | Vice Operations | Profile | |
| Paul Little | Chief Officer | Profile | |
| David Hovland | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.